Aripiprazole for treating irritability associated with autism spectrum disorders

References

• Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord. 2006;36(8):1101–1114.
   PubMed Web of Science ®Google Scholar
• Baio J, Wiggins DL, Christensen MJ. et al. Prevalence of autism spectrum disorder among children aged 8 years - Autism and developmental disabilities monitoring network, 11 sites, United States, 2014. Morbidity Mortality Weekly Rep Surveill Summ. 2018;67(6):1–23.
   PubMed Web of Science ®Google Scholar
• McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems: research units on pediatric psychopharmacology (RUPP) autism network. N Engl J Med. 2002;347(5):314–321.
   PubMed Web of Science ®Google Scholar
• Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev. 2007;(1). Art. No.: CD005040. DOI:10.1002/14651858.CD005040.pub2
   PubMed Web of Science ®Google Scholar
• Campbell M, Lt A, Am S, et al. The effects of haloperidol on learning and behavior in autistic children. J Autism Dev Disord. 1982;12(2):167–175.
   PubMed Web of Science ®Google Scholar
• Campbell M, Armenteros JL, Malone RP, et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry. 1997;36(6):835–843.
   PubMed Web of Science ®Google Scholar
• Omega 3 fatty acids in the treatment of children with autism spectrum disorders. ClinicalTrials.gov Identifier: NCT00467818; [cited 2018 Dec 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT00467818?term=00467818&rank=1
   Google Scholar
• Divalproex sodium vs placebo in childhood/adolescent autism. ClinicalTrials.gov Identifier: NCT00211757; [cited 2018 Dec 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT00211757?term=00211757&rank=1
   Google Scholar
• Oxcarbazepine versus placebo in childhood autism. ClinicalTrials.gov Identifier: NCT00467753; [cited 2018 Dec 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT00467753?term=00467753&rank=1
   Google Scholar
• Safety and effectiveness of d-cycloserine in children with autism. ClinicalTrials.gov Identifier: NCT00198120. Available at https://clinicaltrials.gov/ct2/show/NCT00198120?term=00198120&rank=1
   Google Scholar
• Nuedexta for the treatment of adults with autism. ClinicalTrials.gov Identifier: NCT01630811; [cited 2018 Dec 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT01630811?term=01630811&rank=1 [Accessed 2018 Dec 27
   Google Scholar
• Arbaclofen in children and adolescents with ASD (AIMS2-CT1). ClinicalTrials.gov Identifier: NCT03682978; [cited 2018 Dec 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT03682978?term=03682978&rank=1
   Google Scholar
• Hirsch LE, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2016;(6). Art. No.: CD009043. DOI:10.1002/14651858.CD009043.pub3
   PubMed Web of Science ®Google Scholar
• Abilify (aripiprazole) [package insert]. Rockville (MD): Otsuka America Pharmaceutical, Inc; 2017. [cited 2018 Dec 12].
   Google Scholar
• de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs. 2015;29(9):773–799.
   PubMed Web of Science ®Google Scholar
• Rizzo R, Pavone P. Aripiprazole for the treatment of irritability and aggression in children and adolescents affected by autism spectrum disorders. Expert Rev Neurother. 2016;16(8):867–874.
   PubMed Web of Science ®Google Scholar
• Aman MG, Singh NN, Stewart AW. et al. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Mental Deficiency. 1985;89(5):485–491.
   PubMedGoogle Scholar
• Marcus RN, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110–1119.
   PubMed Web of Science ®Google Scholar
• Owen R, Sikich L, Marcus N, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533–1540.
   PubMed Web of Science ®Google Scholar
• Findling RL, Mankoski R, Timko, et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry. 2014;75(1):22–30.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Sahraeizadeh A, Berk M. A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014;45(2):185–192.
   PubMed Web of Science ®Google Scholar
• Pozzi M, Pisano S, Bertella S, et al. Persistence in therapy with risperidone and aripiprazole in pediatric outpatients: a2-year naturalistic comparison. J Clin Psychiatry. 2016;77:e1601–e1609.
   PubMed Web of Science ®Google Scholar
• Varni JW, Handen BL, Corey-Lisle PK, et al. Effect of aripiprazole 2 to 15 mg/d on health-related qualify of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of the two controlled trials. Clin Ther. 2012;34(4):980–992.
   PubMed Web of Science ®Google Scholar
• Fallah MS, Shaikh MR, Neupane B, et al. Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. J Child Adolesc Psychopharmacol. 2019 Apr;29(3):168–180. . Epub 2019 Feb 1.
   PubMed Web of Science ®Google Scholar
• Orsolini L, Tomasetti C, Valchera A, et al. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf. 2016 Oct;15(10):1329–1347.
   PubMed Web of Science ®Google Scholar
• Marcus RN, Owen R, Manos G, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry. 2011;72(9):1270–1276.
   PubMed Web of Science ®Google Scholar
• Berardis D, Fornaro M, Serroni N, et al. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. Recent Pat Endocr Metab Immune Drug Discov. 2014;8:30–37.
   PubMedGoogle Scholar
• Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000;30:245–255.
   PubMed Web of Science ®Google Scholar
• Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62:1266–1274.
   PubMed Web of Science ®Google Scholar
• Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry. 2007;61:538–544.
   PubMed Web of Science ®Google Scholar
• Wink LK, Early M, Schaefer T, et al. Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole. J Child Adolesc Psychopharmacol. 2014 Mar;24(2):78–82.
   PubMed Web of Science ®Google Scholar
• Pozzi M, Pisano S, Marano G, et al. Weight-change trajectories of pediatric outpatients treated with risperidone or aripiprazole in a naturalistic setting. J Child Adolesc Psychopharmacol. 2018 Nov 16. Epub ahead of print. DOI:10.1089/cap.2018.0092
   PubMed Web of Science ®Google Scholar
• Schoemakers RJ, van Kesteren C, van Rosmalen J, et al. No differences in weight gain between risperidone and aripiprazole in children and adolescents after 12 months. J Child Adolesc Psychopharmacol. 2019 Jan 23. DOI:10.1089/cap.2018.0111.
   PubMed Web of Science ®Google Scholar
• Anagnostou E, Aman MG, Handen BL, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2016 Sep 1;73(9):928–937.
   PubMed Web of Science ®Google Scholar
• Handen BL, Anagnostou E, Aman MG, et al. A randomized, placebo-controlled trial of metformin for the treatment of overweight induced by antipsychotic medication in young people with autism spectrum disorder: open-label extension. J Am Acad Child Adolesc Psychiatry. 2017 Oct;56(10):849–856.
   PubMed Web of Science ®Google Scholar
• Walkup JT, Cottingham E. Antipsychotic-induced weight gain and metformin. J Am Acad Child Adolesc Psychiatry. 2017 Oct;56(10):808–810.
   PubMed Web of Science ®Google Scholar
• Pisano S, Catone G, Veltri S, et al. Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists. Ital J Pediatr. 2016 May 21;42(1):51.
   PubMedGoogle Scholar
• Kauffman YS, Delate T, Botts S. Metabolic monitoring in children 5 years of age and younger prescribed second-generation antipsychotic medications. Ment Health Clin. 2018 Mar 23;7(1):1–6.
   PubMedGoogle Scholar
• Chen W, Cepoiu-Martin M, Stang A, et al. Antipsychotic prescribing and safety monitoring practices in children and youth: a population-based study in Alberta, Canada. Clin Drug Investig. 2018 May;38(5):449–455.
   PubMed Web of Science ®Google Scholar
• Carbon M, Kapoor S, Sheridan E, et al. Neuromotor adverse effects in 342 youth during 12 weeks of naturalistic treatment with 5 second-generation antipsychotics. J Am Acad Child Adolesc Psychiatry. 2015 Sep;54(9):718–727.
   PubMed Web of Science ®Google Scholar
• Pillay J, Boylan K, Carrey N, et al. First- and Second-Generation Antipsychotics in Children and Young Adults: systematic Review Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Mar. PMID: 28749632.
   Google Scholar
• Williamson E, Sathe NA, Andrews JC, et al. Medical therapies for children with autism spectrum disorder—an update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 May. PMID: 29064643.
   Google Scholar
• Michaelson J. Mother’s Little anti-psychotic is worth $6.9 Billion a year. Daily Beast (2014-11-09). Available at https://www.thedailybeast.com/mothers-little-anti-psychotic-is-worth-dollar69-billion-a-year [Accessed 2019 Feb 19
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al., The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(6):e1000097.
   PubMed Web of Science ®Google Scholar